Denosumab use Beyond 12 Months Linked to Higher Osteonecrosis Risk in Prostate Cancer: JAMA

A cohort study in patients with bone-metastatic castration-resistant prostate cancer found that 7–12 months of denosumab treatment was associated with a lower risk of skeletal-related events and a ...
Read the full report on Business Medical Dialogues
Story file
- Section
- Health
- Topics
- Health alerts
- First reported by
- Business Medical Dialogues
- Reporter
- dr riya dave
- Published
- Sunday, 25 October 2026, 8:15 pm IST
- Coverage
- One outlet so far
How this page works. The Headline Update lists this report from Business Medical Dialogues with a short summary and a link to the original. The original reporting and photograph belong to the publisher. Spotted an error in our summary? Tell our corrections desk.




